Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| Ocuphire has a strong balance sheet |
| In all, I see a fantastic opportunity to leverage my business and medical backgrounds to help build out an already exceptional organization that is committed to helping patients and creating value through innovation |
| And so, I think, this is a wonderful thing |
| The positive outcome of our recent end of Phase 2 meeting means that Ocuphire has a clear path to develop a truly game changing drug, and I'm excited by the opportunity to lead this effort |
| The commercial opportunity in diabetic retinopathy is compelling |
| And that's why I think that's part of the reason why we do have a favorable safety and tolerability profile is because we aren't completely decimating the systemic VEGF levels |
| We think that an oral will be well tolerated for this |
| So, that's a -- it's a very exciting time and metabolic disease right now and great things are happening for patients |
| So, there's a real mechanist advantage to the APX, modulation of angiogenesis that's quite elegant and quite favorable for patients |
| I was very impressed by how RYZUMVI had advanced through both clinical development and the FDA approval process in a relatively short timeframe |
| So I'm very pleased to be working with a group of very capable individuals who have proven themselves in the ability to execute on drug development and strategic licensing efficiently and effectively |
| Furthermore, the Company's lead ophthalmic asset, APX3330 represents an even more exciting commercial opportunity |
| I think part of the reason that's favorable is because as you guys know, the Ref-1 modulation that APX does actually reduces in VEGF levels back to a physiologic level |
| I was successful in negotiating a favorable exit through an acquisition with QHP Capital, a transaction that realized significant returns for investors |
| It's a great excitement and a deep sense of responsibility that I step into this role |
| The planned advancement of APX3330 into registrational trial marks an exciting new chapter |
| So in dry AMD and in geographic atrophy in particular where we've seen good uptake in what is a disease where you don't see an immediate sort of dramatic impact like you do in wet AMD or in diabetic macular edema |
| So in the Phase 3, when we power it for that, if we can replicate those, I think we have a very, very meaningful story for not just the FDA, but also for patients |
| In conclusion, I'm excited about the future of Ocuphire my new role here |
| APX3330 offers the promise of an oral agent that can slow the progression of non-proliferative diabetic retinopathy to proliferative diabetic retinopathy |
| And that's much better than waiting until you get, until you have one of the side effects of it like a heart attack or stroke |
| And so far, ours has been favorable |
| I'm very pleased to address you today as the recently appointed CEO of Ocuphire |
| We don't know that in our program, but I think that's an advantage of having an oral over an intravitreal injection or a topical |
| The FDA approval of RYZUMVI this past September was an important milestone for Ocuphire |
| We have a very strong relationship with Viatris and continue to work with them as they direct the clinical development for treatment of presbyopia and dim light disturbances |
| And so, taking a pill every day is very acceptable for this patient population |
| Ocuphire is now at an exciting stage, and my immediate priority as CEO is to develop and implement a strategy to take the Company to the next logical phase of maturation in order to maximize value for shareholders |
| And so, our market research is showing that this should be well received by the community, and that this is the correct indication for an oral |
| Our strategy is rooted in rigorous scientific research and deep understanding of patient needs, and we are building a team with the capabilities to execute and create value |
| Statement |
|---|
| I know from my own practice about the challenges of treating diabetic retinopathy and the devastating impact that it can have on patients |
| The anti-VEGF agents are efficacious, but the majority of moderate to severe patients with DR are not treated with anti-VEGF due to the injection burden and the lack of benefit on immediate visual acuity |
Please consider a small donation if you think this website provides you with relevant information